This inventor holds 1 USPTO granted patent. Top assignee: Abelzeta Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Qingxia Wang: Innovator in Chimeric Antigen Receptor Technology
Introduction
Qingxia Wang is a prominent inventor based in Hong Kong, CN. She has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). Her innovative work focuses on targeting specific antigens to enhance the efficacy of engineered T cells in cancer treatment.
Latest Patents
Qingxia Wang holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in the design and application of CAR technology, specifically aimed at improving therapeutic outcomes for patients.
Career Highlights
Wang is currently associated with Abelzeta Inc., where she continues to push the boundaries of cancer research and treatment. Her work has garnered attention for its potential to revolutionize how certain cancers are treated, particularly those expressing the CD20 antigen.
Collaborations
Throughout her career, Qingxia Wang has collaborated with notable colleagues, including Yihong Yao and Jiaqi Huang. These partnerships have fostered a collaborative environment that enhances innovation and accelerates research progress.
Conclusion
Qingxia Wang is a trailblazer in the field of chimeric antigen receptor technology, with a focus on improving cancer therapies. Her contributions and ongoing research hold promise for the future of immunotherapy.